Philip Morris International
PM
$186.00
-1.88%
Philip Morris International Inc. (PM) is a global tobacco company that manufactures and sells cigarettes and reduced-risk products, including heated tobacco units (IQOS), vapes (Veev), and oral nicotine pouches (Zyn), primarily outside the United States. As a spin-off from Altria in 2008, PM has established itself as a market leader in the transition toward smoke-free alternatives, with IQOS dominating the heated tobacco category and Zyn leading the nicotine pouch segment in key markets. The current investor narrative centers on PM's accelerating growth in reduced-risk products, which now account for a significant portion of revenue, while the company navigates regulatory pressures, currency fluctuations, and the secular decline of traditional cigarettes. Recent attention has been fueled by strong quarterly results, with Q1 2026 revenue up 9.1% year-over-year, and the stock's inclusion in discussions about high-yield dividend investing, as highlighted by recent Motley Fool coverage.…
PM
Philip Morris International
$186.00
Related headlines
Investment Opinion: Should I buy PM Today?
Based on the analysis, PM is rated a Buy. The thesis is that PM's leadership in reduced-risk products, with 43.2% of revenue from smoke-free alternatives, is driving accelerating growth (9.1% YoY in Q1 2026) and justifies a premium valuation. The consensus analyst rating is Buy with an average target price of $203.80, implying an 8.4% upside from the current price of $188.05. The stock offers a dividend yield of 3.46% and a PEG ratio of 0.36, indicating undervaluation relative to growth.
Sign up to view all
PM 12-Month Price Forecast
The AI assessment is bullish on PM, driven by strong fundamental momentum and an attractive valuation. The company's successful transition to reduced-risk products is reflected in accelerating revenue growth and expanding margins. The PEG ratio of 0.36 suggests the market is not fully pricing in the growth potential, offering upside. However, the medium confidence reflects uncertainties around regulatory risks and the sustainability of growth. If PM can maintain revenue growth above 8% and navigate regulatory challenges, the stock is likely to outperform. A downgrade to neutral would occur if growth decelerates below 6% or if regulatory actions significantly impact reduced-risk product sales.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $203.80 and implied upside of +9.6% versus the current price.
Average Target
$203.80
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$175 - $225
Analyst target range
PM is covered by 15 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.75, where 1 is Strong Buy and 5 is Sell). The average target price is $203.80, implying an 8.4% upside from the current price of $188.05, while the low and high targets are $175.00 and $225.00, respectively. The consensus leans bullish, with 10 analysts rating it Buy or Overweight, 4 Hold, and 1 Sell, reflecting confidence in PM's growth strategy and dividend sustainability. The target range of $175 to $225 indicates a 28.6% spread, suggesting moderate uncertainty, with the high target assuming continued success in reduced-risk products and potential multiple expansion, while the low target prices in regulatory risks and slower adoption. Recent ratings actions have been stable, with no downgrades in the past six months, and firms like Morgan Stanley and Needham reiterating Overweight and Buy ratings, respectively, signaling sustained institutional support.
Drowning in data?
Find the real signal!
Bulls vs Bears: PM Investment Factors
PM presents a compelling growth story driven by its leadership in reduced-risk products, which now account for 43.2% of revenue and are growing at a double-digit pace. The stock's valuation, with a PEG of 0.36, suggests it is undervalued relative to its growth potential, and the dividend yield of 3.46% provides a solid income component. However, the premium P/E of 22.06x versus the industry average of 18x leaves little room for disappointment, and regulatory risks loom large. The bull case is currently stronger, supported by accelerating revenue growth and analyst consensus, but the key tension is whether PM can sustain its growth trajectory in the face of regulatory headwinds and the secular decline of cigarettes. If reduced-risk products continue to gain share and regulatory risks remain manageable, the stock could re-rate higher; conversely, any setback could trigger multiple compression.
Bullish
- Strong Revenue Growth Acceleration: Q1 2026 revenue grew 9.1% YoY to $10.146B, up from 6.5% growth in Q1 2025, indicating accelerating momentum. This is driven by reduced-risk products, which now contribute 43.2% of total revenue, up from 38% a year earlier.
- Dominant Smoke-Free Portfolio: IQOS and Zyn lead their categories globally, with reduced-risk product revenue of $4.379B in Q1 2026. The company's strategic pivot to smoke-free alternatives is paying off, as these products are growing faster than traditional cigarettes and command premium pricing.
- Attractive Valuation with PEG of 0.36: The PEG ratio of 0.36x suggests the stock is undervalued relative to its earnings growth rate, which is estimated at 55.6%. This is well below the typical threshold of 1.0, indicating the market is not fully pricing in PM's growth potential.
- High Dividend Yield with Growth: PM offers a dividend yield of 3.46% with a payout ratio of 76%, supported by strong free cash flow of $10.666B TTM. The dividend is well-covered and has a history of increases, making it attractive for income investors.
Bearish
- Premium Valuation vs. Peers: PM trades at a trailing P/E of 22.06x, a 22.6% premium to the industry average of 18x. This premium may be justified by growth, but it leaves little room for error and could compress if growth disappoints.
- Regulatory and Litigation Risks: The tobacco industry faces increasing regulation, including potential bans on flavored products and stricter marketing rules. PM's reduced-risk products are not immune, and any adverse regulatory action could impact growth and profitability.
- High Payout Ratio Limits Flexibility: The dividend payout ratio of 76% leaves limited room for dividend increases or share buybacks, especially if earnings growth slows. This could constrain shareholder returns and make the stock less attractive to income investors.
- Currency and Macro Sensitivity: PM generates revenue globally, and currency fluctuations can significantly impact earnings. With a beta of 0.4, the stock is less volatile than the market, but it is still exposed to economic downturns that could reduce consumer spending on tobacco products.
PM Technical Analysis
PM is currently in a strong uptrend, with the stock price at $188.05 as of August 6, 2026, reflecting a 12.61% gain over the past year. The stock is trading at approximately 90.5% of its 52-week range (low of $142.11, high of $207.76), indicating it is near the upper end of its annual range, which typically signals robust momentum and investor confidence. This positioning suggests the market is rewarding PM's growth trajectory, though it also raises the risk of short-term overextension, especially given the stock's beta of 0.4, which implies lower volatility than the broader market.
Beta
0.40
0.40x market volatility
Max Drawdown
-21.3%
Largest decline past year
52-Week Range
$142-$208
Price range past year
Annual Return
+9.3%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | +2.4% |
| 3m | -0.5% | +4.7% |
| 6m | -0.1% | +11.7% |
| 1y | +9.3% | +21.3% |
| ytd | +16.0% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory is solidly growing, with Q1 2026 revenue of $10.146 billion, up 9.1% year-over-year from $9.301 billion in Q1 2025. This growth is driven by reduced-risk products, which generated $4.379 billion in the quarter, representing 43.2% of total revenue, while combustible products contributed $5.767 billion. The multi-quarter trend shows consistent expansion, with revenue rising from $9.301 billion in Q1 2025 to $10.146 billion in Q1 2026, and the company's full-year 2025 revenue reached $40.7 billion, up from $38.1 billion in 2024. The growth is accelerating, as Q1 2026's 9.1% YoY increase compares favorably to the 6.5% growth seen in Q1 2025, indicating that PM's smoke-free transition is gaining traction.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Given PM's positive net income of $2.438 billion in Q1 2026, the trailing P/E ratio of 22.06x is the primary valuation metric, with a forward P/E of 20.51x, implying a modest 7.0% discount that reflects expected earnings growth. The PEG ratio of 0.36x suggests the stock is undervalued relative to its growth rate, as the market is pricing in a 55.6% earnings growth rate, which is aggressive but supported by the company's expanding reduced-risk product portfolio. Compared to the industry average P/E of approximately 18x for tobacco companies, PM trades at a 22.6% premium, which is justified by its superior growth profile and dominant position in the smoke-free category.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high dividend payout ratio of 76%, which limits financial flexibility, and a negative debt-to-equity ratio of -4.89, indicating that the company has more liabilities than equity, a common situation for tobacco companies with large debt loads. However, PM generates strong free cash flow of $10.666B TTM, which covers its dividend and debt obligations. The current ratio of 0.96 suggests potential liquidity concerns, but this is typical for the industry and not an immediate red flag. Earnings volatility is moderate, with Q4 2024 showing a net loss of -$579M due to one-time charges, but the overall trend is positive, with Q1 2026 net income of $2.438B. The company's reliance on continued growth in reduced-risk products to justify its valuation is a key financial risk, as any slowdown could impact earnings and the stock price.
FAQ
The key risks of holding PM include: (1) Regulatory risk, as governments may impose stricter rules on tobacco and nicotine products, potentially impacting reduced-risk product sales. (2) Competitive risk, as other tobacco companies and new entrants challenge PM's market share in smoke-free products. (3) Financial risk, with a high payout ratio of 76% limiting dividend growth and a negative debt-to-equity ratio indicating high leverage. (4) Macro risk, as economic downturns could reduce consumer spending on tobacco products. The most severe risk is a combination of regulatory crackdowns and slowing growth, which could lead to a 24% decline to the 52-week low of $142.11. Investors should monitor these risks closely.
The 12-month forecast for PM is positive, with a base case target of $203.80 (analyst average), implying 8.4% upside from the current price of $188.05. The bull case target is $225 (analyst high), representing 19.7% upside, with a 30% probability, driven by strong reduced-risk product growth and regulatory approvals. The bear case target is $175 (analyst low), a 6.9% downside, with a 20% probability, if regulatory actions or economic downturn hurt growth. The most likely scenario is the base case, with a 50% probability, assuming continued steady growth. Overall, the stock is expected to appreciate modestly over the next year, with a favorable risk-reward profile.
PM is fairly valued to slightly undervalued based on its growth prospects. The trailing P/E of 22.06x is a 22.6% premium to the industry average of 18x, reflecting PM's superior growth and market position. However, the PEG ratio of 0.36 indicates that the market is pricing in a 55.6% earnings growth rate, which is aggressive but supported by the company's reduced-risk product momentum. The forward P/E of 20.51x implies a 7% discount to the trailing multiple, suggesting expected earnings growth. Compared to its own history, PM's valuation is in line with its five-year average, indicating it is not overvalued. The market is pricing in continued success in smoke-free products, and if that materializes, the stock is undervalued.
PM is a good buy for investors seeking a combination of growth and income, given its 3.46% dividend yield and 9.1% revenue growth in Q1 2026. The stock trades at a P/E of 22.06x, which is a premium to the industry average of 18x, but the PEG ratio of 0.36 suggests it is undervalued relative to its growth rate. The analyst consensus is Buy with an average target of $203.80, implying 8.4% upside. However, the stock is not without risks, including regulatory actions and a high payout ratio of 76%. For investors with a long-term horizon and tolerance for regulatory uncertainty, PM is a solid addition to a diversified portfolio.
PM is more suitable for long-term investment due to its stable business model, low beta of 0.4, and growing dividend. The company's transition to reduced-risk products provides a multi-year growth opportunity, and the stock's low volatility makes it a good fit for income-oriented investors. Short-term trading is possible, but the stock's moderate price movements and sensitivity to regulatory news may limit trading opportunities. A minimum holding period of 3-5 years is recommended to fully capture the benefits of the smoke-free transition and dividend compounding. For investors seeking a defensive, income-generating stock with growth potential, PM is an excellent long-term holding.